Beat, stock falls
Amgen beat on revenue and EPS and reaffirmed guidance, yet shares fell sharply as investors weighed biosimilar pressure on older drugs against the MariTide pipeline.
Sources: https://www.sec.gov/Archives/edgar/data/318154/000031815426000153/amgn-20260930earningsrelea.htm
Previous verdicts for AMGN
- AI Search: Amgen Rallies Sharply as Q3 Beat and Raised Guidance Reverse the Slide — 2026-11-04
- AI Search: Amgen Edges Up Slightly as Technical Setup Builds — 2026-11-02
- AI Search: Amgen Rallies Sharply as Analyst Reaffirmation and Rare Disease News Land — 2026-10-29
- Amgen beats on revenue and EPS — 2026-08-04
- Upgrade sparks violent rally — 2026-05-08
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works